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AP is a neurokinin-1 receptor antagonist with unique anti-
emetic activity. We conducted a phase II trial evaluating efficacy
& safety of AP in combination with 5-HT3 antagonists & ad-
justed dose of dexamethasone (D) in pts receiving high-dose
CY for stem cell mobilization. High-dose CY is associated with
significant nausea & vomiting. CY and filgrastim provides a better
PBPC yield as compared to filgrastim (failure rate15-20%). Pri-
mary endpoint was the control of vomiting without the use of
rescue anti-emetics at 24 hours after high dose CY. Secondary
objectives were to evaluate side effects, control of nausea & de-
layed vomiting. Tertiary objective was to estimate the rate of suc-
cessful CD34+ mobilization (minimum 2 million CD 34+ cells/kg
body weight).
Methods: From May 2005 to June 2009, 40 pts were enrolled,
five of whom were not evaluable for response. All received CY
4gm/m2 and filgrastim (10-16mcg/kg/d). Granisetron 1 mg, (D)
10 mg and AP 125 mg were given orally 1 hour before CY fol-
lowed by AP 80 mg once daily  2 days. We used Simons opti-
mal two-stage design constrained to fewer than 40 pts with 10%
type I error and 85% statistical power. AP is judged to be of suf-
ficient efficacy for further evaluation if it prevents acute vomiting
in. 45% of pts. Under these assumptions, 18 evaluable pts were
enrolled in 1st stage. Acute emesis was controlled in 10 pts
therefore meeting the goal & enrollment proceeded to stage 2.
An additional 17 pts were enrolled in Stage 2. If acute vomiting
is controlled in 20 or more of the 35 pts, AP is judged worthy of
further study.
Results: Twenty out of 35 response-evaluable patients (57%) did
not develop vomiting or require rescue anti-emetics, thus achiev-
ing the critical value for success. A total of 22 (63%) of 35 re-
sponse-evaluable pts met the criterion for the secondaryTable 1. Patients Characteristics
Sex: Male/ Female 20/15
Median Age(years) 48 (range: 23-64)
Race
Caucasians 30
African Americans 4
Native American 1
Diagnosis
APL 1
HD 4
NHL 11
MM 19
Median CD341Cells/kg 7.62 million cells
(range: 1.7 -76.15)
APL: Acute Promyelocytic Leukemia, HD: Hodgkin Disease, MM: Multi-
ple Myeloma, NHL: Non- Hodgkin Lymphomaendpoint of control of delayed vomiting defined as no vomiting
episodes during days 2 – 5 and no rescue medications; exceeding
the critical value for success. Thirty four out of 35 pts had a suc-
cessful stem cell mobilization, thuse far exceeding the critical
value of 23 of 35 pts. Two pts had grade 3 toxicity; 1 had pain
(probably AP related) & another reported diarrhea (possibly AP
related). Thus the rate of serious toxicity was 6% meeting the cri-
terion for acceptable toxicity.
Conclusion:This final analysis demonstrate that AP has potential to
effectively control acute & delayed emesis in pts receiving high-dose
Cy and should be evaluated further.110
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Introduction:Many patients (pts) who are eligible for ASCT are
unable to collect a minimum number of CD34 + stem cells to
support high dose chemotherapy and ASCT. Plerixafor,
a CXCR4 antagonist, in combination with G-CSF mobilizes
more CD34+ stem cells when compared to G-CSF alone. Due
to its cost, we commenced a risk adapted approach to the utili-
zation of plerixafor for stem cell mobilization in pts undergoing
ASCT. Our goal was to add plerixafor in pts who had ineffective
mobilization thereby preventing mobilization failures. Re-mobili-
zation results in added costs, delays with possible disease pro-
gression and time lost for the pts.
Methods: The study was restricted to pts mobilized with 10
mcg/kg/day GCSF alone. There were two patient populations:
those who had plerixafor added in the evening of day 5 if PB
CD 34\10/L with apheresis commencing the following morn-
ing; and those who during apheresis had a daily collection yield
of\0.5  106 CD34/kg. Morning administration of G-CSF and
evening dosing of plerixafor continued daily until apheresis was
complete.
Results: From February to July 2009, 147 mobilization attempts
occurred with G-CSF alone (Myeloma 61, NHL 54, Amyloid 17,
Hodgkin 10, POEMS 4 and 1 solid tumor). Median CD34 yield:
5.5  106 CD34/kg; median apheresis 3. 67 pts (46%) received
plerixafor; 37 during mobilization and 30 during collections.
Overall, 7 of 147 (5%) failed to achieve a minimum of 2 
106 CD34/kg compared to a prior 22% failure rate. Day 4 PB
CD34 count and day 1 apheresis yield were analyzed to predict
who would require plerixafor under these guidelines (Table 1).
72% of pts whose PB CD34\10 on day 4 received plerixafor
vs 10% if $10. 110 pts did not start plerixafor prior to day 1
collection; if day 1 apheresis yield was \1.5, 76% subsequently
received plerixafor.
Conclusions: Implementing this risk adapted approach allows
poor mobilizers to be identified promptly and for initiation of
plerixafor during mobilization and collection, thereby reducing
the number of failures. In pts whose PB CD34\10 on day 4
of G-CSF or whose day 1 yield is \1.5 x106 CD34/kg, earlier
addition of plerixafor may result in fewer apheresis days. Based
on this data, we are implementing the earlier addition of plerix-
afor. This risk adapted approach with early implementation of
plerixafor may be more cost effective than waiting for failureS197
